Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals logo
$401.80 +9.56 (+2.44%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$394.62 -7.18 (-1.79%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
22

Based on 26 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 3 have given a hold rating, and 22 have given a buy rating for ALNY.

Consensus Price Target

$392.13
-2.41% Downside
According to the 26 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $392.13. The highest price target for ALNY is $550.00, while the lowest price target for ALNY is $220.00. The average price target represents a forecasted downside of -2.41% from the current price of $401.80.
Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up

ALNY Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
22 Buy rating(s)
20 Buy rating(s)
21 Buy rating(s)
16 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$392.13$340.00$319.17$269.32
Forecasted Upside-2.41% Downside2.43% Upside23.05% Upside-1.00% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-2.41% Downside10,285.39% Upside14.62% Upside
News Sentiment Rating
Positive News

See Recent ALNY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/1/2025Scotiabank
5 of 5 stars
Greg Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$342.00 ➝ $450.00+12.00%
8/1/2025UBS Group
3 of 5 stars
Eliana Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$403.00 ➝ $550.00+38.02%
8/1/2025Canaccord Genuity Group
2 of 5 stars
Whitney Ijem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$390.00 ➝ $415.00+4.88%
8/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tiago Fauth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$333.00 ➝ $395.00-0.23%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gena Wang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$329.00 ➝ $460.00+17.28%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$304.00 ➝ $449.00+14.47%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ulz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$312.00 ➝ $405.00+3.25%
8/1/2025Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keay Nakae
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$325.00 ➝ $400.00+1.98%
7/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$377.00 ➝ $478.00+21.63%
7/30/2025Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Martin Auster
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$370.00+11.93%
7/21/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$385.00+20.11%
7/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$338.00 ➝ $348.00+11.85%
7/11/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Lebovitz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$364.00 ➝ $404.00+27.91%
7/11/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$336.00 ➝ $359.00+11.27%
7/7/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Maury Raycroft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$328.00 ➝ $384.00+18.58%
6/24/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kostas Biliouris
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$300.00 ➝ $360.00+11.37%
4/2/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$500.00 ➝ $500.00+91.04%
3/31/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joshua Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$353.00+31.49%
3/31/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Paul Matteis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$300.00 ➝ $345.00+28.51%
3/21/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luca Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$310.00 ➝ $330.00+17.29%
3/21/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
1/7/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$314.00 ➝ $310.00+31.53%
11/12/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradePeer Perform ➝ Underperform
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$282.00 ➝ $371.00+25.37%
10/11/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$220.00 ➝ $220.00-21.77%
8/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$198.00 ➝ $370.00+40.85%
6/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$138.00 ➝ $159.00-33.15%
6/25/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Bayko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$210.00 ➝ $260.00+12.40%
10/11/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:27 AM ET.


Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 29, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Recent analyst upgrades have increased price targets significantly, with some analysts setting targets as high as $384.00, indicating strong potential for stock appreciation.
  • The current stock price is around $327, which is near its 52-week high of $333.70, suggesting strong market confidence in the company's performance.
  • Alnylam Pharmaceuticals, Inc. reported a revenue increase of over 20% year-over-year, showcasing its growth potential in the biopharmaceutical sector.
  • The company has received a majority of "buy" ratings from analysts, reflecting positive sentiment and confidence in its future performance.
  • With a market capitalization of approximately $42.63 billion, Alnylam Pharmaceuticals, Inc. is positioned as a significant player in the biopharmaceutical industry, which may attract institutional investors.

Alnylam Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The company has a negative price-to-earnings (P/E) ratio, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio, suggesting that it relies heavily on debt financing, which can increase financial risk.
  • Despite revenue growth, the company reported a loss per share that missed analyst expectations, which may raise concerns about its ability to achieve profitability in the near term.
  • Insider selling activity has been noted, with the CEO selling a significant number of shares, which could signal a lack of confidence in the company's short-term prospects.
  • The stock has experienced volatility, with fluctuations in trading volume, which may deter risk-averse investors.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $392.13, with a high forecast of $550.00 and a low forecast of $220.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 3 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -2.41% based on their 12-month stock forecasts.

Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ALNY compares to other companies.


This page (NASDAQ:ALNY) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners